CYP3A5 Polymorphism in Circulating Tumor Cells Confers an Increased Disease-Free Survival in DLBCL Patients Treated with R-CHOP
In this study, we demonstrated that in CTCs derived from liquid biopsies, the GG genotype in the <i>CYP3A5 A6986G</i>, which is related to the metabolism and elimination of chemotherapy drugs, impacts in longer DFS. These findings confirm the relevance of circulating biomarkers in non-invasive biological samples for strengthening the prognosis of DLBCL.
Authors
- Carlos Martínez‐Murillo (ORCID: https://orcid.org/0000-0002-9950-0472)
- Adolfo Martínez Tovar (ORCID: https://orcid.org/0000-0002-5713-3731)
- Iveth Mendoza Salas
- Christian Omar Ramos Peñafiel (ORCID: https://orcid.org/0000-0003-0957-9090)
- Silvia Jiménez‐Morales (ORCID: https://orcid.org/0000-0002-6590-9712)
- Efreen Horacio Montaño Figueroa
- Rafael Cerón Maldonado (ORCID: https://orcid.org/0000-0003-0935-4107)
- Anel Irais García Laguna (ORCID: https://orcid.org/0000-0002-5308-1292)
- Adrián De la Cruz Rosas (ORCID: https://orcid.org/0000-0001-7137-4059)
- Gilberto Barranco-Lampón (ORCID: https://orcid.org/0000-0002-2988-7544)
- Irma Olarte‐Carrillo (ORCID: https://orcid.org/0000-0002-5374-0534)
Institutions
- Hospital General de México (MX)
- National Institute of Genomic Medicine (MX)
- Instituto de Medicina Genómica (ES)
- Universidad Nacional Autónoma de México (MX)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/ott.s486400
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Consejo Nacional de Ciencia y Tecnología
- Universidad Nacional Autónoma de México